SURVYR

LUCD

Lucid Diagnostics Inc.
$0.33
−$0.02 (5.28%)Oct 21 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-76%-52%-29%-6%+18%Oct 2025Oct 2026Apr 202652w low $0.30
LUCDSPY
Wall St. Highest PT $9.50 (+2749.4%) Wall St. Avg PT $4.00 (+1099.8%)
$0$4$7$10$13POC $1Hi $10Avg $4
Underwater Drawdown %Max DD -77.3%Current -77.3%
0.0%-77.3%
Relative Strength vs SPY-89.7% vs SPYUnderperforming
+103%0%-103%
1W
−$0.21 (38.60%)
1M
−$0.51 (60.54%)
3M
−$0.61 (64.72%)
6M
−$0.98 (74.55%)
YTD
−$0.76 (69.41%)
1Y
−$0.88 (72.45%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Strong Buy
5 analysts · mean score 1.40
1 = Strong Buy · 5 = Sell
Strong Buy360%
Buy240%
Hold00%
Underperform00%
Sell00%
Wall Street consensus · as of Oct 22, 2026
Analyst price targets
Current price$0.33
Average target$4.00
+$3.67 (+1099.8%) upsideaverage target vs current price
CurrentAverageMedian
Low$2.00
Median$3.00
High$9.50
12-month Wall Street target range · as of Oct 1, 2026
Recent analyst rating changes · 8
Reiterated
2026-08-27 · Ascendiant Capital reiterated Buy on LUCD
Reiterated
2026-08-17 · BTIG reiterated Buy on LUCD
Reiterated
2026-06-08 · Ascendiant Capital reiterated Buy on LUCD
Reiterated
2026-05-15 · Maxim Group reiterated Buy on LUCD
Reiterated
2026-05-15 · BTIG reiterated Buy on LUCD
Reiterated
2026-04-09 · Ascendiant Capital reiterated Buy on LUCD
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$63.7M
P/E (next 12 months, estimated)-2.0
52-week range$0.30 – $1.63
Revenue growth (latest quarter vs a year ago)+26.7%
Dividend yieldNo dividend
Average analyst price target$4.00 (+1100%)

What they do

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. The company's flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device.

Healthcare · Medical Devices
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for LUCD yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

LUCD earningsNext report in 14 days
Next report · quarter Sep 2026
Wed Nov 11, 2026Before the open
EPS consensus-$0.06 range -$0.06–-$0.05
Revenue consensus$1.6M 5 analysts
Last 4 quarters · EPS vs estimate
Aug 12, 2026-$0.06est -$0.05−9.1%Below estimates
May 13, 2026-$0.07est -$0.06−10.5%Below estimates
Mar 25, 2026-$0.10est -$0.09−15.4%Below estimates
Nov 12, 2025-$0.10est -$0.09−15.4%Below estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · refreshed 2026-10-21 18:34:51 ET
24-1125-0325-0525-0825-1126-0326-0526-08-0.200.00
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$1.5M+26.7%
2026-03-31$1.3M–
2025-12-31$1.5M–
2025-09-30$1.2M–
2025-06-30$1.2M–

News & catalysts

More news
Lucid Diagnostics Advances Multiple EsoGuard® and EsoCheck® Payment, Billing and Coding Pathways
PR Newswire · Sep 22
Lucid Diagnostics (LUCD) Q2 2026 Earnings Call Transcript
Motley Fool · Aug 20
Lucid Diagnostics Eyes Medicare Catalyst for EsoGuard Growth
MarketBeat · Aug 15
PAVmed Inc. Q2 2026 Earnings Call Summary
Moby · Aug 14
PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results
PR Newswire · Aug 14
Rating changes
Reiterated
2026-08-27 · Ascendiant Capital reiterated Buy on LUCD
Reiterated
2026-08-17 · BTIG reiterated Buy on LUCD
Reiterated
2026-06-08 · Ascendiant Capital reiterated Buy on LUCD
Reiterated
2026-05-15 · Maxim Group reiterated Buy on LUCD
Reiterated
2026-05-15 · BTIG reiterated Buy on LUCD
Reiterated
2026-04-09 · Ascendiant Capital reiterated Buy on LUCD

Third-party analyst actions, not SURVYR.'s views. All rating changes

Stats refreshed 2026-10-21 18:34:51 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026